Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS

Background: Low-doses of bone modifying agents (LD-BMAs) compared to those used to treat bone metastases are used in breast or prostate cancer patients on adjuvant endocrine therapy to prevent Cancer Treatment Induced Bone Loss (CTIBL). Their use is associated with an increased risk of developing Me...

Cijeli opis

Bibliografski detalji

Glavni autori:	Francesco Bertoldo, Cristina Eller-Vainicher, Vittorio Fusco, Rodolfo Mauceri, Jessica Pepe, Alberto Bedogni, Andrea Palermo, Umberto Romeo, Giuseppe Guglielmi, Giuseppina Campisi
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-02-01
Serija:	Journal of Bone Oncology
Teme:	Osteonecrosis of the jaw Breast cancer Prostate cancer CTIBL Denosumab Bisphosphonate
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2212137424001362
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!